جست‌وجوی استاد و پژوهشگر

• Oncology
• Molecular Biology
• Cancer Immunotherapy
• +۳ مورد دیگر

Katia Reda serves as a Contract Professor at the Department of Law, Economics and Sociology (DiGES) of the Università della Calabria (UniCZ). Her research focuses on innovative cancer therapies, particularly targeting hematologic malignancies and solid tumors through molecular mechanisms involving non-coding RNAs, immunotherapy, and targeted drug delivery systems. She has pioneered studies on bispecific T-cell engagers, G-quadruplex stabilization, and CRISPR-based approaches to identify novel therapeutic targets. Her work integrates bioinformatics, preclinical models, and clinical trial analysis to advance precision oncology. Key contributions include identifying MALAT1 triplex inhibitors and exploiting the cGAS/STING pathway in immunogenic cell death mechanisms. Katia's interdisciplinary approach bridges molecular biology, pharmacology, and immunology to address challenges in cancer treatment efficacy and resistance. Notably, her research has explored the role of miR-221/222 in cancer progression and the application of resveratrol in epigenetic modulation. She has also contributed to understanding genetic anomalies in rare cases of SRY-positive females through non-invasive prenatal testing insights. Despite her affiliation with the DiGES department, her research activities are primarily aligned with medical and life sciences disciplines, reflecting a transdisciplinary academic profile.

Aditi Mulgaonkarمشاهده پروفایل

مدرس

• Molecular Imaging
• Nanomedicine
• Cancer Detection
• +۴ مورد دیگر

Aditi Mulgaonkar, Ph.D., is an Instructor in the Department of Radiology at UT Southwestern Medical Center, affiliated with its Radiology Research Division. She previously served as a senior research associate in the Cyclotron and Radiochemistry Program, supporting Dr. Xiankai Sun's work on theranostic macromolecules. Her research focuses on radiotherapeutic nanoseeds, cancer theranostics, and antibody-based tumor detection using PET imaging, resulting in 14 peer-reviewed publications. Dr. Mulgaonkar holds a pharmacy degree from the University of Mumbai, a Ph.D. in pharmaceutical sciences from Virginia Commonwealth University, and postdoctoral training at the FDA and UT Southwestern. Her research interests emphasize molecular imaging advancements, particularly in bacterial infections and cancer diagnostics. She is a member of the Society of Nuclear Medicine and Molecular Imaging and contributes to editorial roles in journals like EC Pharmaceutical Science and International Journal of Nanomedicine. Her work spans drug transport studies, nanocrystal synthesis, and imaging techniques for CAR T-cell therapy. Ongoing projects include developing novel HIF2a PET tracers and refining immunoPET imaging for PD-L1 expression in renal cell carcinoma models. Her contributions bridge clinical translation and precision medicine, with a focus on nanotheranostics and radiolabeling strategies.

Lois Woodsمشاهده پروفایل

پژوهشگر

• Evidence Synthesis
• Systematic Reviews
• Healthcare Information Science
• +۳ مورد دیگر

Lois Woods is a Senior Research Assistant at the University of Southampton, affiliated with the Southampton Health Technology Assessments Centre (SHTAC). She specializes in information science and evidence synthesis, contributing to systematic reviews and clinical trial methodologies. Her role involves designing search strategies, critical appraisal of evidence submissions for NICE, and supporting projects like the StOP UTI initiative to prevent urinary tract infections in care homes. She holds a postgraduate degree in Information Science and previously worked at Public Health England as a librarian. Lois actively participates in Cochrane Crowd and collaborates on interdisciplinary projects, including EU-funded research on immunomodulatory therapies for drug-resistant pneumonia. Her work spans healthcare resources, public health, and life sciences, emphasizing evidence-based practices. She also co-chairs the InterTASC ISSG and contributes to teaching systematic review methodologies. Her research interests include digital tools for clinical trial recruitment, healthcare resource optimization, and translational research. Lois has co-authored numerous publications on topics ranging from prostate cancer diagnostics to gene therapy, reflecting her expertise in evidence synthesis and health technology assessment.

Kevin Angstadtمشاهده پروفایل

استادیار

• Computer Architecture
• Programming Languages
• Software Engineering
• +۳ مورد دیگر

Kevin Angstadt is an Assistant Professor of Computer Science at St. Lawrence University, part of the Department of Mathematics, Computer Science, and Statistics. He holds a Ph.D. from the University of Michigan (2020) and an MCS from the University of Virginia (2016), with undergraduate degrees in Computer Science, Mathematics, and German Studies from St. Lawrence University (2014). His research focuses on the intersection of computer architecture, programming languages, and software engineering, with an emphasis on optimizing programming support for emerging hardware technologies like accelerators and autonomous systems. Education: Ph.D. in Computer Science and Engineering, University of Michigan (2020) M.S. in Computer Science, University of Virginia (2016) B.S. in Computer Science, Mathematics, and German Studies, St. Lawrence University (2014) Research Interests: His work spans programming abstractions for hardware accelerators, fault-tolerant autonomous systems, and tools like MNRL and MNCaRT for automata processing. He also collaborates on projects such as StatKey, a statistical simulation tool used by over one million users. Recent Articles Trends: His publications emphasize hardware-software co-design, resilience in autonomous systems, and debugging support for pattern-matching languages. Recent work includes NSF-funded research on program repair and optimization, and frameworks like LOGI and START for secure autonomous vehicle operation. Awards: NSF Medium Grant ($1.2M, 2022) UVA Teaching and Service Award (2017) Jefferson Scholars Foundation Fellow (2014–2017) Best in Session Award at TECHCON 2016 Advising & Grants: He leads a $1.2M NSF grant and has advised projects on pattern-matching accelerators, autonomous vehicle resilience, and compiler optimization. Collaborates with industry and academic partners on mission-critical systems and software reliability. Labs/Teams: Core contributor to MNRL (automata processing ecosystem), StatKey (statistical tools), and the START project for resilient autonomous systems. Active in open-source development and hardware-accelerator research groups.

• Macromolecular Chemistry
• Drug Delivery Systems
• Nanogels
• +۷ مورد دیگر

Professor Lutz Nuhn is Chair of Macromolecular Chemistry at the Julius Maximilian University Würzburg since April 2022, where he leads the Macromolecular Therapeutics Research Group. His research focuses on designing novel polymeric drug delivery systems at the interface between materials chemistry and life science, with particular emphasis on nano-sized vaccines and anti-cancer immunotherapies. Faculty of Chemistry and Pharmacy, Julius Maximilian University Würzburg (2022-present) Emmy-Noether research group leader funded by DFG (2019-2022) Young group leader at Max Planck Institute for Polymer Science (2017-2022) Professor Nuhn's research explores the design of well-defined block copolymers with self-assembling and responsive properties for developing nano-sized carriers that can sense various stimuli including temperature, pH or light. These biodegradable nanocarriers disassemble under physiologically relevant conditions and are engineered for selective immune responses against intracellular pathogens and cancer. His work particularly emphasizes novel strategies to modulate the immune regulatory properties of the tumor microenvironment to combat cancer via next generation nano-immunotherapeutics. Analysis of Professor Nuhn's recent publications reveals a strong focus on pH-responsive nanocarriers, macrophage-targeted therapies, and cancer immunotherapies. His work spans from fundamental polymer chemistry to translational applications, with particular emphasis on liver cancer treatment, macrophage repolarization, and vaccine development. The research demonstrates a consistent trajectory toward increasingly sophisticated nanocarrier systems with multiple responsive elements and targeting capabilities. Liebig fellow of the FCI Emmy-Noether research group leader (DFG) Scholarships from German National Academic Foundation, Max Planck Graduate Center, FCI, AvH, and FWO Professor Nuhn leads the Macromolecular Therapeutics Research Group which develops innovative polymer-based nanocarriers for immunotherapy applications. His research has been supported by multiple grants including the DFG Collaborative Research Center SFB-1066 'Nanodimensional Polymer Therapeutics for Tumor Therapy' where he leads projects focused on treating liver tumors and polymer-induced tumor immunotherapy. The group maintains active collaborations with immunologists, cancer researchers, and clinicians to translate their nanocarrier designs into clinically relevant therapies.

• Hematology
• Oncology
• Immunology
• +۳ مورد دیگر

Prof. Vago Luca Aldo Edoardo is an Associate Professor in the Department of Medicine at Vita-Salute San Raffaele University. His research focuses on hematological malignancies, immunotherapy, and stem cell transplantation, with a particular emphasis on blood diseases and viral complications post-transplantation. He teaches hematology courses for medical students and coordinates specialized programs in blood and immune system diseases. Prof. Vago holds editorial roles at BLOOD journal and serves on scientific committees for organizations like the American Society of Hematology (ASH) and Center for International Blood and Marrow Transplant Research (CIBMTR). His work integrates clinical research with translational studies, addressing challenges in leukemia treatment, gene therapy applications, and immune response modulation. Affiliations: Vita-Salute San Raffaele University Roles: Associate Professor, Researcher in Hematology, Editorial Board Member (BLOOD), Scientific Committee Member (ASH, CIBMTR) Research Interests: Leukemia pathogenesis, allogeneic stem cell transplantation, HLA compatibility, immunomodulatory therapies, and viral reactivation in transplant patients. His work often explores the intersection of genetic factors and clinical outcomes in hematological disorders. Advising/Grants: Leads research projects on T-cell engineering and post-transplant immune recovery, collaborating internationally. His grants focus on improving therapeutic strategies for blood cancers and optimizing transplantation protocols.

Nai-Kong Cheungمشاهده پروفایل

استاد

• Pediatric Oncology
• Immunotherapy
• Antibody Engineering
• +۳ مورد دیگر

Nai-Kong Cheung, MD, PhD is the Enid A. Haupt Chair in Pediatric Oncology at Memorial Sloan Kettering Cancer Center (MSKCC), Department of Pediatrics. He leads the Nai-Kong Cheung Lab focused on engineering antibodies and immune cells to treat pediatric solid and liquid tumors. His work integrates antibody-based therapies, CAR-T cell engineering, and pretargeted radioimmunotherapy strategies targeting antigens like GD2, HER2, and GPA33. Education: MD/PhD in Immunology from Harvard Medical School. Key affiliations include the Center for Experimental Therapeutics and Gerstner Sloan Kettering Graduate School. His research addresses challenges in neuroblastoma immunotherapy, including clonal evolution, tumor vasculature targeting, and combination therapies with checkpoint inhibitors. Notable techniques: Development of SADA bispecific antibodies, pretargeted α-particle radiotherapy, and ex vivo T-cell arming strategies. Current projects explore theranostic approaches for colorectal and ovarian cancers, and optimizing antibody responses via β-glucan adjuvants. Labs/Teams: The lab includes researchers specializing in immunology, molecular biology, and translational oncology. Open postdoctoral positions focus on antibody engineering and clinical trial development.

Arielle Elkriefمشاهده پروفایل

دانشیار بالینی

• Oncology
• Immunology
• Microbiology
• +۳ مورد دیگر

Arielle Elkrief is a Clinical Associate Professor in the Department of Medicine at the University of Montreal and holds a dual appointment in the Department of Oncology at the Centre hospitalier de l’Université de Montréal (CHUM). She serves as Co-Director of the CHUM Microbiome Centre and is a Research Member of the Montreal Cancer Institute (ICM). Her work bridges clinical oncology and translational research, focusing on the gut and tumor microbiome as biomarkers and therapeutic targets in cancer immunotherapy. Elkrief leads microbiome-centered clinical trials, including fecal microbiota transplantation (FMT), prebiotics, and dietary interventions to enhance immunotherapy efficacy. She has contributed pivotal research on the negative impact of antibiotics on immunotherapy outcomes and developed strategies to mitigate immune-related adverse events like colitis through FMT. Her lab integrates computational biology, microbiology, and oncology to advance precision medicine. Elkrief has published over 75 peer-reviewed articles in journals such as Nature Medicine, Journal of Clinical Oncology, and Clinical Cancer Research. She has received prestigious awards including the American Society of Clinical Oncology Young Investigator Award and the SITC-MRA Women in Melanoma Fellowship. Her research also explores genomic and immune correlates of therapy response in lung and melanoma cancers. She collaborates broadly, including with the Terry Fox Research Institute and the Canadian Cancer Centres Network, to translate microbiome insights into clinical practice.

• Chloroplast biotechnology
• Non-food crops
• Protein secretion
• +۵ مورد دیگر

Francesca De Marchis is a Senior Researcher at the Institute of Biosciences and BioResources (IBBR), part of the National Research Council of Italy (CNR), based at the Perugia Division. With over two decades of experience in plant biotechnology research, she has established herself as a leading expert in chloroplast engineering and unconventional protein secretion pathways in plants. Her educational background includes a PhD in "Biology and Ecology" from the University of Perugia (2011-2014) and a Degree in Biological Sciences from the same institution (1992-1997). Dr. De Marchis's research primarily focuses on chloroplast biotechnology , where she has pioneered methods for genetic engineering of tobacco chloroplasts to accumulate proteins of agronomic, pharmaceutical and industrial interest. Her work extends to non-food crops for producing proteins with industrial and pharmaceutical applications, and she has made significant contributions to understanding protein secretion mechanisms in plant cells, particularly unconventional trafficking pathways. Her research has resulted in numerous publications, with an Scopus H-index of 17 and WOS H-index of 16, demonstrating substantial impact in her field. Analysis of her recent publications reveals a strong emphasis on plant-based biopolymer production, chloroplast transformation techniques, and the application of plant systems for pharmaceutical protein production. Her work bridges fundamental molecular biology with practical applications in sustainable materials and therapeutics. Throughout her career, Dr. De Marchis has progressed from research fellow positions to her current role as Senior Researcher, maintaining continuous employment at IBBR-CNR since 2000. Her research has been consistently funded through institutional support from CNR, enabling sustained investigation into plant biotechnology applications. She collaborates extensively within the IBBR network and with researchers across multiple institutions, focusing particularly on chloroplast engineering applications for biopolymer production and protein secretion mechanisms in plant cells.

• Neuroscience
• Immunology
• Cancer Biology
• +۳ مورد دیگر

Dr. Sebastien Talbot is an Associate Professor at Queen's University's Department of Biomedical and Molecular Sciences, affiliated with the School of Medicine and Faculty of Health Sciences. His research focuses on neuro-immune interactions, particularly in host defense mechanisms and chronic inflammatory diseases. He holds a PhD in Neurobiology from Harvard Medical School (2017) and a BSc in Pharmacology from Université de Sherbrooke (2006). Research interests include neuro-immune cross-talk in cancer, immune tolerance mechanisms, and the role of sensory neurons in immunological processes. His lab develops innovative therapies targeting neural-tumor microenvironment interactions and employs advanced bioprinting technologies (e.g., LIST laser-assisted cell printing). Key collaborations involve mesenchymal stromal cell engineering and immunoproteasome-based vaccines. Recent work emphasizes neuro-immune pathways in cancer immunotherapy resistance, pain modulation in chronic diseases, and the interplay between nerves and tumor progression. Articles highlight discoveries in neurogenic inflammation, cytokine signaling, and neuronal circuits affecting immunity. No specific awards are listed, but his work is supported by grants and collaborations with institutions like the Queen's Laboratory for Molecular Pathology. Laboratory activities include bioprinting technologies for neural and immune cell models, preclinical testing of novel therapeutics, and systems-level analysis of neuroimmune networks. Dr. Talbot maintains an active Google Scholar profile and lab website for further details.

• Autoimmune Liver Diseases
• Drug-Induced Liver Injury
• Hepatotoxicity
• +۳ مورد دیگر

Lily Dara, MD, is an Assistant Professor of Medicine at the Keck School of Medicine of the University of Southern California, where she serves as an NIH-funded physician-scientist specializing in hepatology. Board-certified in both Internal Medicine and Gastroenterology, she maintains active clinical practices at Los Angeles General Medical Center for inpatient liver services and subspecialty clinics, and performs endoscopic procedures at Keck Hospital of USC's outpatient endoscopy unit. Dr. Dara's research centers on drug-induced liver injury mechanisms using translational animal models and human studies, with particular focus on hepatotoxicity from medications, toxins, and herbal supplements. As an investigator for the NIH's Drug Induced Liver Injury Network (DILIN) and LiverTox reviewer, she examines immune-mediated injury pathways including checkpoint inhibitor toxicity. Her work also investigates racial and ethnic disparities in autoimmune liver disease outcomes, especially among Hispanic/Latinx populations with Autoimmune Hepatitis and Primary Biliary Cholangitis. Analysis of her 15 most recent publications (2019-2025) reveals dominant research themes in immune-mediated liver injury mechanisms, particularly checkpoint inhibitor toxicity and drug-induced autoimmune-like hepatitis. Her work consistently explores cell death pathways (apoptosis/necroptosis), genetic susceptibility factors, and ethnic disparities in disease presentation and outcomes, demonstrating strong translational focus bridging basic science with clinical hepatology. Dr. Dara's scientific recognition includes: NIH, NIDDK: K08 Mentored Clinical Scientist Development Award (2016-2021) Keck School of Medicine: USC RCLD Junior Faculty Transition Award (2015) AASLD: Presidential Poster of Distinction (2011) AASLD: Resident Scholar Award (2007) Her NIH K08 award established her independent research program in drug-induced liver injury, and she continues as active DILIN investigator with ongoing clinical trial participation. While specific mentoring activities aren't detailed, her Assistant Professor role involves training medical students, residents, and fellows in hepatology through USC's academic medical system. Dr. Dara collaborates with USC's Liver Institute research teams focusing on translational mechanisms of liver injury and clinical outcomes in diverse patient populations.

• Immunotherapy
• Cancer Research
• CAR T-Cell Therapy
• +۳ مورد دیگر

Peisheng Hu is a Research Assistant Professor of Pathology (Part-Time) at the University of Southern California. His work focuses on advancing immunotherapeutic strategies for cancer, particularly in CAR T-cell therapy, antibody engineering, and biomedical imaging. He has contributed to understanding the pharmacokinetics of antibody-based therapeutics and their biodistribution in preclinical models. Research Interests: Dr. Hu's research spans CAR T-cell therapy, tumor immunology, and the development of novel immunoconjugates. He explores how engineered antibodies and fusion proteins can modulate the immune system to combat malignancies. His work also addresses challenges in targeting solid tumors and improving the efficacy of combination therapies. Publications Highlight: Recent studies include the spatiotemporal tracking of CAR T-cells via PET imaging and the design of humanized CAR constructs with improved signaling. Earlier work includes foundational studies on antibody-CpG conjugates and fusion proteins targeting tumor-associated antigens. Advising & Grants: No formal advisee list is provided, but his publications suggest active collaboration in translational oncology. Grants and funding details are not detailed in the provided text.

• Cancer Therapeutics
• Molecular Oncology
• Angiogenesis
• +۳ مورد دیگر

Overview Parkash Singh Gill, MD is a Professor of Medicine, Pathology, and Urology at the University of Southern California (USC), holding the Renette and Marshall Ezralow Family Chair in Cancer Therapeutics. He specializes in oncology and molecular medicine, focusing on novel therapeutic targets in tumors and their vascular systems. His research bridges basic science and clinical translation, with contributions to FDA-approved cancer drug development and clinical trial leadership. Education & Affiliations: Professor at USC's Keck School of Medicine Member of the FDA Advisory Committee for Biologics Research Interests: Dr. Gill’s work centers on identifying and validating molecular targets such as Eph receptors (EphB4, Ephrin-B2), GRP78, and Axl tyrosine kinase. His studies explore these targets' roles in cancer progression, angiogenesis, and immune evasion, with applications in drug development and precision medicine. Publications: His recent work emphasizes EphrinB2 inhibition in renal cell carcinoma (2023), GRP78’s role in SARS-CoV-2 entry (2021), and EphB4’s therapeutic potential in AML (2017). These studies highlight trends toward combinational therapies (e.g., PD-1 blockade with ILC2 modulation) and translational imaging techniques (e.g., PET/CT for lymph node metastasis detection). Grants & Awards: While specific awards are not listed, his leadership roles and FDA approvals reflect significant recognition in oncology research. Advising & Mentorship: No formal advisee list provided, but his clinical trials and drug development efforts suggest extensive collaboration with research teams. Labs & Teams: Not explicitly stated, but his work implies affiliation with multidisciplinary groups in translational oncology and molecular therapeutics at USC.

Arutha Kulasingheمشاهده پروفایل

پژوهشگر ارشد

• Tumor Microenvironment
• Head and Neck Cancer
• Lung Cancer
• +۳ مورد دیگر

Dr Arutha Kulasinghe is a Research Fellow at Queensland University of Technology (QUT) within the School of Medicine, Faculty of Health. His research focuses on spatial profiling of tumor microenvironments, liquid biopsy technologies, and immunotherapy biomarkers for head and neck cancers and lung cancer. He holds a PhD from QUT (2017) and an Honours degree in Medical Microbiology from the University of Pretoria. Supported by NHMRC, Cure Cancer, and GPRWMF grants, his work bridges clinical and translational research. Key achievements include developing PD-L1 biomarkers for head and neck cancers, spatial mapping of tumor-immune interactions, and identifying SARS-CoV-2 placental dysfunction signatures. He leads the Clinical-oMx Lab at Frazer Institute, University of Queensland, and collaborates with national/international institutions. Awards include the Peter Doherty NHMRC Early Career Fellowship and the AusBiotech Dual COVID-19 Award for biomarker triage systems. Education: PhD (QUT, 2017), BSc (Honours) Medical Microbiology (Pretoria, South Africa) Research Themes: Spatial biology, liquid biopsies, tumor microenvironment dynamics, immunotherapy response prediction Funding Agencies: NHMRC, Cure Cancer Australia, Garnett Passe & Rodney Williams Memorial Foundation Dr Kulasinghe's lab focuses on translating spatial multi-omics data into clinical tools for personalized cancer therapy. Current projects include digital spatial profiling of head and neck tumors and predictive biomarker development for immunotherapy.

• Autoimmune Diseases
• Immunology
• Protein Modifications
• +۴ مورد دیگر

Hester Doyle, PhD, is a Research Scientist in the Department of Rheumatology, Allergy, & Immunology at Yale School of Medicine. Her research focuses on protein modifications in autoimmune diseases, immunology, and infectious diseases. She holds a PhD from the University of Oklahoma (1998), MSc (1995), and BS (1992). Education: PhD, University of Oklahoma, 1998 MSc, University of Oklahoma, 1995 BS, Baldwin Wallace University, 1992 Her work explores mechanisms of autoimmunity, including post-translational protein modifications affecting T cell function and antigen recognition. Key projects include studies on oxidative stress in autoimmune pathology, EGFR peptide-based cancer immunotherapy, and CD4+ T cell responses to fungal pathogens like Cryptococcus neoformans. Publications span topics like lupus autoantigens, histone stability, and chemokine roles in host defense. Collaborations with Mark Mamula, Mei-Ling Yang, and others highlight interdisciplinary research in immunology and protein biochemistry.